Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer

The polo-like kinase PLK2 has recently been identified as a potential theranostic marker in the management of chemotherapy sensitive cancers. The methylation status of the PLK2 CpG island varies with sensitivity to paclitaxel and platinum in ovarian cancer cell lines. Importantly, extrapolation of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Coley, Helen M., Hatzimichael, Eleftheria, Blagden, Sarah, McNeish, Iain, Thompson, Alastair, Crook, Tim, Syed, Nelofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2012
Materias:
Research Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292894/
https://www.ncbi.nlm.nih.gov/pubmed/22289679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292894/
https://www.ncbi.nlm.nih.gov/pubmed/22289679

Ejemplares similares